Well-Managed Myelodysplastic Syndrome Patients Treated with Traditional Korean Medicine; Report of Two Cases = 한방 치료를 통한 골수이형성증후군 치험례 2례

다국어 초록 (Multilingual Abstract)

Myelodysplastic syndrome (MDS) is a typical myeloid malignancy characterized by cell dysplasia in bone marrow. Currently, there is no therapeutic treatment for MDS. The only available therapies either relieve symptoms or prevent the development of acute myeloid leukemia (AML). This study aimed to report the effects of traditional Korean medicine (TKM) on MDS by presenting two case reports. The patient in Case 1 was diagnosed with primary MDS and regularly received acupuncture treatments and herbal medicine. In Case 2, a patient with ovarian cancer was diagnosed with secondary MDS, which resulted from an adverse reaction to chemotherapy. This patient took herbal medicine for four years and was hospitalized three times. In order to have their condition evaluated, both patients underwent regular blood tests. The patient in Case 1, who showed blood transfusion dependency, received only two blood transfusions after TKM treatment, and the person’s health condition was stable as of January 2016 without any signs of AML development. The patient in Case 2 also has stable health condition. TKM treatment effectively treated their MDS symptoms and improved their general health conditions without any adverse effects. It also prevented the rapid development of AML and maximized the effects of conservative therapy.

참고문헌 (Reference)

1 이남헌, "항암단으로 치료한 암환자 100례의 혈청 VFGF, bEGF 및 platelet 수치 변화" 대한한방내과학회 26 (26): 753-760, 2005

2 김병수, "삼원적 구조로 본 상수역학 체계- 四象？五行？六氣를 중심으로 -" 한의병리학회 21 (21): 1065-1071, 2007

3 Malcovati L, "Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes" 25 (25): 3503-3510, 2007

4 Padron E, "The clinical management of chronic myelomonocytic leukemia" 12 (12): 172-178, 2014

5 Disperati P, "Progression of myelodysplasia to acute lymphoblastic leukaemia: implications for disease biology" 30 (30): 233-239, 2006

6 Tricot GJ, "Prognostic factors in the myelodysplastic syndromes" 16 (16): 109-115, 1992

7 Komrokji RS, "Prognostic factors and risk models in myelodysplastic syndromes" 13 (13): S295-S299, 2013

8 Malcovati L, "Predicting survival and leukemic evolution in patients with myelodysplastic syndrome" 91 (91): 1588-1590, 2006

9 Eun-Hye Park, "Nationwide statistical analysis of myeloid malignancies in Korea: incidence and survival rate from 1999 to 2012" 대한혈액학회 50 (50): 204-217, 2015

10 Cazzola M, "Myelodysplastic syndromescoping with ineffective hematopoiesis" 352 (352): 536-538, 2005

11 Song HW, "Literature review on practical use of Sibjeondaebo-tang" 4 (4): 153-172, 1996

12 Lee MH, "Experimental studies on the hematopoietic effects of Cervi pantotrichum Cornu" Graduate school of Daejeon university 2001

13 Rollison DE, "Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs" 112 (112): 45-52, 2008

14 García-Delgado R, "Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia" 38 (38): 744-750, 2014

15 Sekeres MA, "Characteristics of US patients with myelodysplastic syndromes:results of six cross-sectional physician surveys" 100 (100): 1542-1551, 2008

16 Aul C, "Age-related incidence and other epidemiological aspects of myelodysplastic syndromes" 82 (82): 358-367, 1992

17 Klepin HD, "Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Adults" 32 (32): 2541-2552, 2014

18 Kim JD, "A case of myelodysplastic syndrome" 20 (20): 274-279, 1999